Fusobacterium nucleatum is a common bacterium that lives in our mouths, often without causing any ill effects, although it is also frequently the culprit in gum disease.
Gilad Bachrach at the Hebrew University of Jerusalem, Israel, and his colleagues incubated F nucleatum together with a variety of human tumour cells and natural killer cells, and found that the bacterium inhibited the killer cells' ability to attack cancer.
Researchers also found that a bacterial protein called Fap2 binds to a receptor on the natural killer cells called TIGIT, 'New Scientist' reported.
Whether this interaction is a coincidence or a deliberate strategy on the part of the bacterium remains unclear, but the relationship between it and cancer is probably a mutually beneficial one, researchers said.
F nucleatum prefers anaerobic - low-oxygen - environments, and tumours are often precisely that.
"The purpose of this pathogen is not to kill the host; it is to survive. Maybe by preventing these tumours from being killed, the bacterium creates a sheltered niche in which to proliferate," said Yiping Han of Columbia University in New York.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
